Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was downgraded by research analysts at Robert W. Baird from a “neutral” rating to an “underperform” rating in a report issued on Tuesday. They currently have a $408.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s price objective would suggest a potential downside of 13.09% from the company’s previous close.

The analysts wrote, “nothing to scoff at,” Skorney said in his downgrade note. However, investor expectations for a strong performance has “stretched the valuation beyond what is reasonable” based on the initial launch metrics (see Skorney’s track record here).In fact, investor expectation shifted from “high” in late April/May to “extraordinary” today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis’ blockbuster therapy, Cosentyx.”We believe shares reflect a greater degree of optimism than is warranted,” Skorney emphasized. “We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408.”

Other equities research analysts have also issued reports about the company. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Piper Jaffray Companies upped their price target on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research report on Tuesday, June 20th. Cowen and Company restated a “hold” rating and issued a $380.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, May 15th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 25th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $477.91.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.09% during trading on Tuesday, hitting $469.68. The stock had a trading volume of 484,690 shares. The firm has a market cap of $49.58 billion, a price-to-earnings ratio of 56.86 and a beta of 1.66. The firm’s 50-day moving average is $499.39 and its 200 day moving average is $422.69. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business’s revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.82 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals will post $14.83 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Downgraded by Robert W. Baird to Underperform” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/regeneron-pharmaceuticals-inc-nasdaqregn-downgraded-by-robert-w-baird-to-underperform.html.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 136,050 shares of the business’s stock in a transaction on Friday, June 2nd. The shares were bought at an average cost of $478.17 per share, for a total transaction of $65,055,028.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael S. Aberman sold 2,269 shares of the firm’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total value of $1,208,060.98. Following the completion of the sale, the senior vice president now owns 9,193 shares in the company, valued at $4,894,537.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. Reynolds Capital Management boosted its stake in Regeneron Pharmaceuticals by 40.0% in the fourth quarter. Reynolds Capital Management now owns 2,100 shares of the biopharmaceutical company’s stock worth $1,140,000 after buying an additional 600 shares in the last quarter. Terra Nova Asset Management boosted its stake in Regeneron Pharmaceuticals by 9.7% in the third quarter. Terra Nova Asset Management now owns 5,945 shares of the biopharmaceutical company’s stock worth $2,765,000 after buying an additional 524 shares in the last quarter. Henderson Group PLC boosted its stake in Regeneron Pharmaceuticals by 17.1% in the fourth quarter. Henderson Group PLC now owns 28,299 shares of the biopharmaceutical company’s stock worth $15,360,000 after buying an additional 4,129 shares in the last quarter. Jennison Associates boosted its stake in Regeneron Pharmaceuticals by 10.9% in the third quarter. Jennison Associates now owns 1,922,133 shares of the biopharmaceutical company’s stock worth $894,061,000 after buying an additional 189,407 shares in the last quarter. Finally, National Pension Service boosted its stake in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock worth $33,920,000 after buying an additional 6,481 shares in the last quarter. Institutional investors own 66.70% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.